Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* No fever on day of vaccination~* History of varicella or residence in a VZV-endemic area for ≥30 years~* Females of reproductive potential must have a negative pregnancy test and must agree to use acceptable methods of birth control~Exclusion Criteria:~* History of hypersensitivity reaction to any vaccine component~* Prior receipt of any varicella or zoster vaccine~* Prior history of herpes zoster~* Have recently had another vaccination~* Pregnant or breastfeeding~* Use of immunosuppressive therapy~* Known or suspected immune dysfunction~* Concomitant antiviral therapy

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ZOSTAVAX™ (AMP) (Type: EXPERIMENTAL): ZOSTAVAX™ manufactured with an alternative process
- ZOSTAVAX™ (Type: ACTIVE_COMPARATOR): ZOSTAVAX™ manufactured with the current process

Based on this trial design, predict the completion outcome and termination type (if applicable).